< Tamara Minko Ph.D. EOHSI Directory | EOHSI

Tamara Minko Ph.D. » EOHSI Directory

A B C D E F G H I J K L M N O P R S T U W Y Z

Tamara Minko Ph.D.

Distinguished Professor – Chair, Department of Pharmaceutics Rutgers University – Ernest Mario School of PharmacyEOHSI – Toxicology
Work William Levine Hall Room 214 160 Frelinghuysen Road Piscataway NJ 08854 Work Phone: 848-445-0145 Work Fax: 732-445-3134
Photo of Tamara Minko Ph.D.

Biographical Info

Dr. Tamara Minko is a Professor II and Chair of the Department of Pharmaceutics at Rutgers, The State University of New Jersey. She is also a member of the Cancer Institute of New Jersey, Environmental and Occupational Health Sciences Institute. Her current research interests include drug delivery; biopharmaceutics; nanotechnology; molecular targeting; antisense oligonucleotides, siRNA and peptide delivery; mechanisms of multidrug resistance; intracellular fate and molecular mechanisms of action of anticancer drugs; bioimaging; macromolecular therapeutics; preclinical evaluation of new therapeutics; modulation of cell death mechanisms during hypoxia.

Professor Minko is author and co-author of more than 400 publications (peer-reviewed papers, books and textbook chapters, conference proceedings, patents). Many of her papers are well cited and published in prestigious journals with high impact factors including PNAS, Nature Nanotechnology, Cancer Research, Clinical Cancer Research, Advanced Drug Delivery Review, Journal of Controlled Release, etc. Dr. Minko is a Fellow of the American Association of Pharmaceutical Scientists, elected member of the Board of Scientific Advisors of the Controlled Release Society, recipient of numerous awards, Editor of Pharmaceutical Research, member of editorial board of several scientific journals and a member of Study Sections at NIH, DOD, American Heart Association and other national and international review panels. Her research is supported by grants from NIH, NSF, DOD and other national and international sources.

Research Areas

Biopharmaceutics; nanotechnology; molecular targeting; antisense oligonucleotides, siRNA and peptide delivery; mechanisms of multidrug resistance; intracellular fate and molecular mechanisms of action of anticancer drugs; bioimaging; macromolecular therapeutics; preclinical evaluation of new therapeutics; modulation of cell death mechanisms during hypoxia.

Ongoing/Recent Research Support

  • 07/01/10 – 05/31/15. NIH/NCI R01CA138533, T. Minko – Principal Investigator. Multifunctional Nanotherapeutics for Cancer Treatment and Imaging.
  • 04/01/03 – 07/31/12. NIH/NCI R01 CA100098, T. Minko – Principal Investigator, Targeted Proapoptotic Anticancer Drug Delivery System.
  • 04/07/06 – 02/28/12. NIH/NCI R01 CA111766, T. Minko – Principal Investigator. Molecular Targeting of Drug Delivery System to Cancer.
  • 09/01/10 – 07/31/15. U54CA151881, T. Minko – Principal Investigator, Combination Nanotherapeutic Strategies to Overcome Tumor Drug Resistance.
  • 07/01/09 – 06/30/12. NIH/NIBIB R01 EB008278, T. Minko – Co-Investigator. Efficient Cellular Delivery of Oligonucleotides. (Principal Investigator – Dr. C. M. Roth, Department of Chemical & Biochemical Engineering, Rutgers University).
  • 12/01/09 – 11/30/12. National Science Foundation CBET 0933966, T. Minko – Co-Principal Investigator. Novel Self Assembly of siRNA for Efficient and Safe Delivery. (Principal Investigator – Dr. H. He, Department of Chemistry, Newark, Rutgers University).
  • Ongoing Research Support:
  • 07/01/10 – 05/31/15. NIH/NCI R01CA138533, T. Minko – Principal Investigator. Multifunctional Nanotherapeutics for Cancer Treatment and Imaging.
  • 10/01/09 – 09/31/11. NIH/NCI (ARRA) R01 CA100098, T. Minko – Principal Investigator, Targeted Proapoptotic Anticancer Drug Delivery System.
  • 04/07/06 – 02/28/12. NIH/NCI R01 CA111766, T. Minko – Principal Investigator. Molecular targeting of drug delivery system to cancer.
  • 09/01/10 – 07/31/15. U54CA151881, T. Minko – Principal Investigator, Combination nanotherapeutic strategies to overcome tumor drug resistance.
  • 07/01/09 – 06/30/11. NIH/NIBIB R01 EB008278, T. Minko – Co-Investigator. Efficient Cellular Delivery of Oligonucleotides. (Principal Investigator – Dr. C. M. Roth, Department of Chemical & Biochemical Engineering, Rutgers University).
  • 09/15/06 – 06/30/11. NIH/NIBIB R01 EB007049, T. Minko – Co- Principal Investigator. Carrier Shape Matters: Filomicelles, Long-circulation, and the EPR effect. (Principal Investigator – Dr. D. Discher, University of Pennsylvania).
  • 12/01/09 – 11/30/12. National Science Foundation CBET 0933966, T. Minko – Co-Principal Investigator. Novel Self Assembly of siRNA for Efficient and Safe Delivery. (Principal Investigator – Dr. H. He, Department of Chemistry, Newark, Rutgers University).
  • 07/01/10 – 06/30/11. Department of Defense Lung Cancer Research Program W81XWH-10-1-0347, T. Minko Co-Investigator (Principal Investigator – Dr. O. Taratula, Postdoctoral Research Associate working under the supervision of Dr. Minko). Innovative Strategy for Treatment of Lung Cancer: Inhalatory Co-Delivery of Anticancer drugs and siRNA for Suppression of Cellular Resistance.

Research Highlights

  • Nanotechnology based inhalatory treatment of lung cancer
  • Targeted multifunctional approach for treatment of multidrug resistant cancer and prevention of metastases
  • Prevention of cellular hypoxic damage by the suppression of Jun N-Terminal Kinase 1

Scholarly Activities

  • 2010 Member (Elected), Board of Scientific Advisors, Controlled Release Society
  • 2009 Fellow of the American Association of Pharmaceutical Scientists (AAPS)
  • 2008, 2010, 2011 Controlled Release Society Outstanding Pharmaceutical Paper Award
  • 1998 The Jorge Heller Journal of Controlled Release/Controlled Release Society Outstanding Paper Award

Recent Publications

  1. Majumder, J, Taratula, O, Minko, T. Nanocarrier-based systems for targeted and site specific therapeutic delivery. Adv. Drug Deliv. Rev. 2019;144 :57-77. doi: 10.1016/j.addr.2019.07.010. PubMed PMID:31400350 PubMed Central PMC6748653
  2. Zang, X, Lee, JB, Deshpande, K, Garbuzenko, OB, Minko, T, Kagan, L. Prevention of paclitaxel-induced neuropathy by formulation approach. J Control Release. 2019;303 :109-116. doi: 10.1016/j.jconrel.2019.04.013. PubMed PMID:30981814 PubMed Central PMC6708409
  3. Khatri, P, Desai, D, Minko, T. On the plasticizing properties of divalproex sodium: physicochemical and spectroscopic characterization studies. Pharm Dev Technol. 2019;24 (4):455-464. doi: 10.1080/10837450.2018.1514049. PubMed PMID:30396305
  4. Shaik, T, Rather, GM, Bansal, N, Minko, T, Garbuzenko, O, Szekely, Z, Abali, EE, Banerjee, D, Kerrigan, JE, Scotto, KW et al.. Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lung cancer and prostate cancer. Oncotarget. 2018;9 (70):33249-33257. doi: 10.18632/oncotarget.26064. PubMed PMID:30279956 PubMed Central PMC6161789
  5. Al-Mahmood, S, Sapiezynski, J, Garbuzenko, OB, Minko, T. Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res. 2018;8 (5):1483-1507. doi: 10.1007/s13346-018-0551-3. PubMed PMID:29978332 PubMed Central PMC6133085
  6. Garbuzenko, OB, Ivanova, V, Kholodovych, V, Reimer, DC, Reuhl, KR, Yurkow, E, Adler, D, Minko, T. Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s). Nanomedicine. 2017;13 (6):1983-1992. doi: 10.1016/j.nano.2017.04.005. PubMed PMID:28434932 PubMed Central PMC5546883
  7. Sapiezynski, J, Taratula, O, Rodriguez-Rodriguez, L, Minko, T. Precision targeted therapy of ovarian cancer. J Control Release. 2016;243 :250-268. doi: 10.1016/j.jconrel.2016.10.014. PubMed PMID:27746277 PubMed Central PMC5191987
  8. Savla, R, Minko, T. Nanoparticle design considerations for molecular imaging of apoptosis: Diagnostic, prognostic, and therapeutic value. Adv. Drug Deliv. Rev. 2017;113 :122-140. doi: 10.1016/j.addr.2016.06.016. PubMed PMID:27374457
  9. Dorrani, M, Garbuzenko, OB, Minko, T, Michniak-Kohn, B. Development of edge-activated liposomes for siRNA delivery to human basal epidermis for melanoma therapy. J Control Release. 2016;228 :150-158. doi: 10.1016/j.jconrel.2016.03.010. PubMed PMID:26965957
  10. Yin, PT, Shah, S, Pasquale, NJ, Garbuzenko, OB, Minko, T, Lee, KB. Stem cell-based gene therapy activated using magnetic hyperthermia to enhance the treatment of cancer. Biomaterials. 2016;81 :46-57. doi: 10.1016/j.biomaterials.2015.11.023. PubMed PMID:26720500 PubMed Central PMC4715938
Search PubMed
Categories: Faculty, Toxicology
Updated 11 months ago.
Skip to toolbar